Prognostic and predictive role of epidermal growth factor receptor mutation in recurrent pulmonary adenocarcinoma after curative resection

European Journal of Cardio-thoracic Surgery

Volumn 47, Issue 3, 2015, Pages 556-562

  Jeon, Jae Hyun ^a   Kang, Chang Hyun ^a   Kim, Hye Seon ^a   Seong, Yong Won ^b   Park, In Kyu ^a   Kim, Young Tae ^a  

^a Seoul National University Hospital   (South Korea)

^b Seoul National University Boramae Hospital   (South Korea)

Author keywords

Adenocarcinoma of lung; Biological; Epidermal growth factor; Mutation; Receptor; Recurrence; Thoracic surgery; Tumour markers

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; PROTEIN TYROSINE KINASE INHIBITOR; EGFR PROTEIN, HUMAN; TUMOR MARKER;

ADULT; ARTICLE; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURGERY; CANCER SURVIVAL; CLINICAL EFFECTIVENESS; DISEASE FREE INTERVAL; DISEASE SEVERITY; FEMALE; GENE MUTATION; HUMAN; LUNG ADENOCARCINOMA; MAJOR CLINICAL STUDY; MALE; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; SMOKING; SURVIVAL RATE; TREATMENT RESPONSE; ADENOCARCINOMA; AGED; DISEASE FREE SURVIVAL; ENZYMOLOGY; GENETIC PREDISPOSITION; GENETICS; LUNG NEOPLASMS; MIDDLE AGED; MUTATION; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; RETROSPECTIVE STUDY;

ADENOCARCINOMA; AGED; DISEASE-FREE SURVIVAL; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RETROSPECTIVE STUDIES; TUMOR MARKERS, BIOLOGICAL;

EID: 84928198468     PISSN: 10107940     EISSN: 1873734X     Source Type: Journal    
DOI: 10.1093/ejcts/ezu177     Document Type: Article

References (25)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T et al. Cancer statistics, 2008. CA Cancer J Clin 2008;58:71-96.
2. al-Kattan K, Sepsas E, Fountain SW, Townsend ER. Disease recurrence after resection for stage I lung cancer. Eur J Cardiothorac Surg 1997;12:380-4.
3. Martin J, Ginsberg RJ, Venkatraman ES, Bains MS, Downey RJ, Korst RJ et al. Long-term results of combined-modality therapy in resectable non-small-cell lung cancer. J Clin Oncol 2002;20:1989-95.
4. Pignon JP, Tribodet H, Scagliotti GV, Douillard JY, Shepherd FA, Stephens RJ et al. Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group. J Clin Oncol 2008;26:3552-9.
5. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004;350:2129-39.
6. Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, Gabriel S et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004;304:1497-500.
7. Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009;361:947-57.
8. Mitsudomi T, Morita S, Yatabe Y, Negoro S, Okamoto I, Tsurutani J et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol 2010;11:121-8.
9. Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, Isobe H et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 2010;362:2380-8.
10. Kim YT, Seong YW, Jung YJ, Jeon YK, Park IK, Kang CH et al. The presence of mutations in epidermal growth factor receptor gene is not a prognostic factor for long-term outcome after surgical resection of non-small-cell lung cancer. J Thorac Oncol 2013;8:171-8.
11. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-16.
12. Martini N, Bains MS, Burt ME, Zakowski MF, McCormack P, Rusch VW et al. Incidence of local recurrence and second primary tumors in resected stage I lung cancer. J Thorac Cardiovasc Surg 1995;109:120-9.
13. Sugimura H, Nichols FC, Yang P, Allen MS, Cassivi SD, Deschamps C et al. Survival after recurrent non-small-cell lung cancer after complete pulmonary resection. Ann Thorac Surg 2007;83:409-17; discussion 17-8.
14. Lee DH, Park K, Kim JH, Lee JS, Shin SW, Kang JH et al. Randomized phase III trial of gefitinib versus docetaxel in non-small cell lung cancer patients who have previously received platinum-based chemotherapy. Clin Cancer Res 2010;16:1307-14.
15. Saisho S, Yasuda K, Maeda A, Yukawa T, Okita R, Hirami Y et al. Post-recurrence survival of patients with non-small-cell lung cancer after curative resection with or without induction/adjuvant chemotherapy. Interact CardioVasc Thorac Surg 2013;16:166-72.
16. Tsao AS, Liu D, Lee JJ, Spitz M, Hong WK. Smoking affects treatment outcome in patients with advanced non-small cell lung cancer. Cancer 2006;106:2428-36.
17. Guo NL, Tosun K, Horn K. Impact and interactions between smoking and traditional prognostic factors in lung cancer progression. Lung Cancer 2009;66:386-92.
18. Ichinose Y, Yano T, Yokoyama H, Inoue T, Asoh H, Tayama K et al. Postrecurrent survival of patients with non-small-cell lung cancer undergoing a complete resection. J Thorac Cardiovasc Surg 1994;108:158-61.
19. Okami J, Taniguchi K, Higashiyama M, Maeda J, Oda K, Orita N et al. Prognostic factors for gefitinib-treated postoperative recurrence in nonsmall cell lung cancer. Oncology 2007;72:234-42.
20. Yamazaki K, Sugio K, Yamanaka T, Hirai F, Osoegawa A, Tagawa T et al. Prognostic factors in non-small cell lung cancer patients with postoperative recurrence following third-generation chemotherapy. Anticancer Res 2010; 30:1311-5.
21. Walsh GL, O'Connor M, Willis KM, Milas M, Wong RS, Nesbitt JC et al. Is follow-up of lung cancer patients after resection medically indicated and cost-effective? Ann Thorac Surg 1995;60:1563-70; discussion 70-2.
22. Hung JJ, Jeng WJ, Hsu WH, Wu KJ, Chou TY, Hsieh CC et al. Prognostic factors of postrecurrence survival in completely resected stage I non-small cell lung cancer with distant metastasis. Thorax 2010;65:241-5.
23. Shimada Y, Saji H, Yoshida K, Kakihana M, Honda H, Nomura M et al. Prognostic factors and the significance of treatment after recurrence in completely resected stage I non-small cell lung cancer. Chest 2013;143:1626-34.
24. Eberhard DA, Johnson BE, Amler LC, Goddard AD, Heldens SL, Herbst RS et al. Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J Clin Oncol 2005;23:5900-9.
25. Kosaka T, Yatabe Y, Onozato R, Kuwano H, Mitsudomi T. Prognostic implication of EGFR, KRAS, and TP53 gene mutations in a large cohort of Japanese patients with surgically treated lung adenocarcinoma. J Thorac Oncol 2009;4:22-9.